Mavacamten is a first-in-class cardiac myosin ATPase inhibitor. approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM). Here. we present the real-world use of mavacamten in 50 patients with oHCM at a tertiary care referral center. https://lightspeedlovers.shop/product-category/spanking-paddles-and-floggers/